3rd Operationalise: Early Access Programmes Summit Europe
R&D
This annual meeting is dedicated to fostering open dialogue and sharing experiences in navigating the complex regulatory and operational landscape of Early Access Programmes. Join a community of over 140 experts in Access, Clinical Operations, Medical Affairs, and Clinical Supply from leading companies such as Novartis, Biogen, Eli Lilly, Gilead, Incyte, and more.
Explore the full agenda here: https://ter.li/5eolwx
Benefits of attending include:
- Identify the essential data required to develop a reliable supply forecasting model for predicting patient request volume, in collaboration with Novartis
- Determine which data should be collected, avoided, and mandated across different European countries to comply with regulatory standards, with expert insights from Roche
- Explore the most effective strategies to support patient journeys and enhance education and awareness about EAPs from the patient’s perspective
- Understand the role of forecasting in planning for Early Access Programs to ensure efficient resource allocation, presented by GSK
- Examine the regulatory, budgeting, and anticipated challenges of EAPs across various indications with AstraZeneca
Find our more here: https://ter.li/5eolwx
